AbbVie (NYSE: ABBV) has entered a new collaboration with life sciences AI platform Valkai to apply purpose-built AI across targeted areas of clinical research, aiming to generate insights faster and support shorter development timelines.
Novo and Anthropic announced a September 16, 2026 collaboration pairing Claude Science with Novo’s R&D teams to tackle drug discovery challenges and strengthen AI-driven software engineering, with financial terms undisclosed.
Charles River Laboratories has completed automation of its Endosafe Cartridge Technology manufacturing suite in Wilmington, Massachusetts, reporting double-digit gains in productivity, capacity and product consistency ahead of full operational scale-up in Q3 2026.
IQVIA has launched IQVIA Predictive Clinical Development, an AI-powered platform built with Anthropic, AWS, Databricks, Microsoft, NVIDIA, Palantir and Snowflake, designed to help sponsors bring new therapies to market up to two years faster.
Abbott Libre Duo 10 Day has received FDA authorization as the world’s first dual glucose-ketone biowearable, designed to alert people with diabetes to rising DKA risk while tracking glucose in real time.
IQVIA’s AI-enabled Clinical Decision Support Tool, built with Breakthrough T1D, won the 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year after cutting T1D misdiagnosis screening workload by 99.5% and lifting diagnostic yield 127-fold.
Amgen data breach headlines have put the biotechnology giant at the center of the healthcare industry’s escalating cybersecurity crisis. Amgen Inc. disclosed on July 31, [Read More…]
Charles River Laboratories will supply GMP-grade Next Generation Sequencing (NGS) and viral safety release testing to Arovella Therapeutics for its ALA-101 CAR-iNKT cell therapy. The tie-up follows FDA acceptance of NGS-based viral safety testing in Arovella’s IND for treating CD19+ B-cell lymphomas and leukemias.
Following a rejected $25 million extortion attempt, a cybercriminal group claims to have stolen 1.3 terabytes of sensitive data in a sophisticated Novo Nordisk cyber attack targeting proprietary drug files and AI systems.
Novo Nordisk A/S has confirmed an IT security breach involving unauthorized access to limited internal systems and data exfiltration. Core operations remain unaffected.
